Summary
Abbott Laboratories announced on October 11, 2019, that its Board of Directors has authorized a new share repurchase program of up to $3 billion of the company's common shares. This significant capital return initiative underscores the company's confidence in its financial health and its commitment to enhancing shareholder value. The new authorization is incremental to the existing $795 million remaining under a previous repurchase program initiated in September 2014. The company intends to execute these repurchases opportunistically, considering market conditions and regulatory requirements, signaling a flexible approach to managing its capital structure.
Key Highlights
- 1Abbott's Board of Directors authorized a new $3 billion share repurchase program.
- 2The new authorization demonstrates confidence in the company's financial stability and prospects.
- 3This program aims to return capital to shareholders and enhance shareholder value.
- 4The $3 billion is in addition to an existing $795 million unused repurchase authorization.
- 5Repurchases will be executed opportunistically based on market conditions and regulatory considerations.
- 6The repurchases may be made from time to time over an unspecified period.
Frequently Asked Questions
The primary purpose of this 8-K filing is to announce that Abbott Laboratories' Board of Directors has authorized a new share repurchase program of up to $3 billion for the company's common shares.
Abbott is authorizing up to $3 billion for new share repurchases, in addition to approximately $795 million remaining from a prior authorization, indicating a substantial commitment to returning capital to shareholders.
The repurchases may be made from time to time as market conditions warrant and subject to regulatory considerations. The filing does not specify a fixed timeline for the completion of the program.
No, the new $3 billion authorization is in addition to the unused portion of the previous share repurchase program from September 2014, which has $795 million remaining.